ISO 20417:2026 Guide: FDA Rec# 5-149, July 1 2029 DoC Window & ISO 15223-1

Operational guide to ISO 20417:2026: FDA Rec# 5-149 complete recognition, the July 1 2029 DoC transition window, ISO 15223-1, 21 CFR 801, and EU MDR GSPR 23.

When the International Organization for Standardization (ISO) published ISO 20417:2026 (Medical devices — Information to be supplied by the manufacturer, Second edition 2026-03) and the U.S. Food and Drug Administration (FDA) promptly added it to Recognition List Number 066 as Recognition Number (Rec#) 5-149, regulatory affairs, labeling, and quality systems teams faced an immediate barrage of consultant commentary claiming that technical files referencing the 2021 first edition were instantly obsolete.

The statutory reality is far more structured and manageable.

ISO 20417:2026 is a horizontal consensus standard, not a self-executing statutory regulation. In the United States, 21 CFR Part 801 (including section 801.15 for stand-alone symbols), 21 CFR Part 809 for in vitro diagnostic (IVD) labeling, and 21 CFR Part 660 for biologics labeling of diagnostic substances for biological products remain the governing legal labeling requirements. In the European Union, Annex I, Chapter III of the EU Medical Device Regulation (EU MDR 2017/745) (General Safety and Performance Requirement 23 / GSPR 23) and of the In Vitro Diagnostic Regulation (EU IVDR 2017/746) (GSPR 20) remain the governing legal information requirements.

Furthermore, on Recognition List Number 066 (Federal Register Doc. 2026-17229, 91 FR 54715, applicable August 24, 2026), FDA formally granted Complete Recognition to ISO 20417:2026 under Rec# 5-149 while establishing a published transition window: FDA will continue to accept Declarations of Conformity (DoCs) in support of premarket submissions citing the superseded Rec# 5-135 (ISO 20417:2021 First edition, corrected version 2021-12) until July 1, 2029.

This operational guide provides the manufacturer decision tree for ISO 20417:2026: what the standard governs versus what it leaves to statutory law, how the FDA transition window functions across 510(k), De Novo, and PMA filings, how ISO 20417 interacts with ISO 15223-1 symbols and electronic instructions for use (eIFU), why European Committee for Standardization (CEN) publication does not automatically confer Official Journal presumption of conformity, and what actions manufacturers should execute over a 30/60/90-day timeline.

Executive Summary: ISO 20417:2026 at a Glance

Parameter	Official Status & Regulatory Reality	Primary Authority / Source Basis
Standard Identity	ISO 20417:2026 (Medical devices — Information to be supplied by the manufacturer), Second edition 2026-03. Replaces ISO 20417:2021.	International Organization for Standardization (ISO catalogue; prepared by ISO/TC 210)
Scope & Mandate	Horizontal standard defining what information needs to be supplied with a medical device or accessory. Explicitly does not dictate the specific delivery format (e.g., paper vs eIFU vs QR code). Specific product/group standards take precedence.	ISO 20417:2026 Scope & Official Public FAQ; FDA Supplementary Information Sheet (SIS) Scope
FDA Recognition	Rec# 5-149 (Standard Identification No. 47133), Specialty Task Group: General I (Quality System / Risk Management), Complete Recognition. Entry date May 25, 2026; FR List 066 applicable August 24, 2026.	FDA CDRH Standards Database; 91 FR 54715–54721 (Docket No. FDA-2004-N-0451)
FDA DoC Transition Period	FDA will accept Declarations of Conformity to Rec# 5-135 (ISO 20417:2021 First edition, corrected 2021-12) in premarket submissions until July 1, 2029.	FDA SIS Rec# 5-149 Transition Period; corroborated by FDA consensus standards database
Relationship to ISO 15223-1	ISO 20417 defines the information content to be supplied; ISO 15223-1 defines the standardized graphical symbols used to convey that information (FDA Rec# 5-148 includes AMD1:2025; Rec# 5-134 transition runs to Dec 17, 2028).	21 CFR 801.15; FDA SIS Rec# 5-148 / 5-134
U.S. Statutory Overlay	Voluntary consensus standard under Section 514(c) of the FD&C Act. Mandatory statutory labeling controls remain 21 CFR Part 801, 809 (IVD labeling), and 660 (biologics labeling).	21 CFR Parts 801, 809, 660; FDA Voluntary Consensus Standards Guidance
EU MDR / IVDR Status	European adoption (EN ISO 20417:2026) is a technical standardization step. It does not confer automatic MDR Article 8 presumption of conformity until cited in the Official Journal of the European Union (OJEU). MDR GSPR 23 and IVDR GSPR 20 remain the legal requirements.	EU MDR 2017/745 Annex I GSPR 23; EU IVDR 2017/746 Annex I GSPR 20; Commission Standardization Request M/575
Statutory Government Fees	$0.00. There is no FDA or CMS user fee to "use" or declare conformity to ISO 20417. MDUFA user fees attach only if a labeling modification triggers a new feeable premarket submission.	FDA MDUFA FY 2027 fee schedule

Is ISO 20417:2026 a New Labeling Law, or a Horizontal Standard for Information Supplied by the Manufacturer?

A foundational misconception in medical device regulatory affairs is conflating international voluntary consensus standards with statutory legislation. ISO 20417:2026 is not a law. It is an international horizontal standard prepared by ISO Technical Committee ISO/TC 210 (Quality management and corresponding general aspects for medical devices).

"Information Supplied by the Manufacturer" vs. Statutory "Labeling"

In traditional regulatory vocabularies such as the U.S. Federal Food, Drug, and Cosmetic Act (FD&C Act Section 201(m)), "labeling" encompasses all labels and other written, printed, or graphic matter upon any article or any of its containers or wrappers, or accompanying such article.

Internationally, the International Medical Device Regulators Forum (IMDRF) clarified this terminology in IMDRF/GRRP WG/N52 FINAL:2024 (Edition 2) (Principles of Labelling for Medical Devices and IVD Medical Devices, published April 26, 2024). IMDRF defines "labeling" as the label, instructions for use (IFU), and any other information that is related to identification, technical description, intended purpose, and proper use of the medical device, explicitly noting that some jurisdictions refer to this collective corpus as "information supplied by the manufacturer."

ISO 20417 serves as the horizontal umbrella standard establishing common, baseline requirements for:

Information on the medical device label (the label affixed directly to the device or device body);
Information on the packaging (unit packs, sales packaging, transport packaging);
Instructions for use (IFU), user manuals, operator manuals, and technical descriptions;
Accompanying documentation, including cleaning, disinfection, and sterilization instructions.

What Changed in the Second Edition (ISO 20417:2026)?

According to the official ISO catalogue page (retrieved 31 August 2026), ISO 20417:2026 replaces ISO 20417:2021 and has been technically revised. The public page identifies three categories of update; it does not republish the paywalled clause text:

Revised normative references. The catalogue does not list the replacement editions on the public page. Gap assessments should open the purchased 2026 text and map each cited normative reference against the editions already declared in the technical file.
Introduction of an "applicable policy" concept. Treat this as a prompt to map the horizontal standard onto the legal overlay of the authority having jurisdiction (for example 21 CFR Part 801 in the United States and MDR GSPR 23 / IVDR GSPR 20 in the EU), not as a substitute for those rules.
Removal of several informative annexes. Do not assume that a 2021 annex table still appears in the 2026 edition, and do not copy consultant annex reconstructions as ISO text. The same public FAQ states that ISO 20417 complements risk-management approaches such as those described in ISO 14971. That is a complementarity statement, not a finding that every information element is copied from a usability protocol.

The "What" vs. "How" Separation

The most critical principle of ISO 20417 is established in its Scope and reinforced in the official ISO Public FAQ:

ISO 20417 defines what information needs to be supplied, but not the specific means or format used to provide that information.

Whether instructions are provided in printed paper format, hosted as an electronic instruction for use (eIFU) on a compliant website, embedded within device software firmware, or accessed via a QR code or data matrix carrier is governed by the specific rules of the target market (for example Commission Regulation (EU) 2021/2226 as amended by Regulation (EU) 2025/1234 in the EU, or FD&C Act section 502(f) and 21 CFR Part 801 in the US).

Furthermore, product-specific or group-specific standards take precedence. Under the established ISO/IEC standardization hierarchy:

Product or group standards: Particular marking, labeling, or information clauses in a product or group standard take precedence over ISO 20417 where they conflict. IEC 60601-1 clause 7 (marking and accompanying documents) is a typical electrical-equipment example. ISO 80369 is a DoC-window sibling for how FDA transition dates work, not a second labeling statute. ISO 10993-1 is the List 066 biocompatibility sibling (Rec# 2-313); it is not a substitute labeling standard.
Horizontal baseline: ISO 20417 supplies the general information-content framework where those product or group standards are silent.

What Did FDA Rec# 5-149 Change on Recognition List Number 066, and Until When Can a DoC Cite Rec# 5-135?

On August 24, 2026, the FDA published Modifications to the List of Recognized Standards, Recognition List Number: 066 (91 FR 54715–54721, Docket No. FDA-2004-N-0451) under the authority of Section 514(c) of the FD&C Act (21 U.S.C. 360d(c)).

FDA Recognition Details: Rec# 5-149 vs. Rec# 5-135

In Table 1 of Recognition List 066 under Specialty Task Group Area E. General I (Quality System / Risk Management), FDA published the official modification:

Item No. / Area	Old Rec#	Replacement Rec#	Title & Designation	Change Description
General I (QS/RM)	5-135	5-149	ISO 20417 Second edition 2026-03 Medical devices - Information to be supplied by the manufacturer	Withdrawn and replaced with newer version

According to the FDA CDRH Standards Database Supplementary Information Sheet (SIS) for Standard Identification No. 47133:

Recognition Number: 5-149
Recognition List Number: 066
Date of Entry: May 25, 2026
Extent of Recognition: Complete standard
Relevant CFR Sections: 21 CFR 660, 21 CFR 801, 21 CFR 809, 21 CFR 820 / QMSR
Supportive Publications: 81 FR 38911 (Final Rule on Use of Symbols in Labeling), IMDRF/GRRP WG/N52 FINAL:2024 (Edition 2), IMDRF/GRRP WG/N47 FINAL:2024, 78 FR 58786 (UDI Final Rule), and FDA Guidance Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices (September 2018).

The Published July 1, 2029 Declaration of Conformity Window

The single most critical operational fact for regulatory affairs professionals is the exact text of the FDA Supplementary Information Sheet regarding transition:

Transition Period: "FDA recognition of ISO 20417 First edition 2021-04 Corrected version 2021-12 [Rec# 5-135] will be superseded by recognition of ISO 20417 Second edition 2026-03 [Rec# 5-149]. FDA will accept declarations of conformity, in support of premarket submissions, to Rec# 5-135 until July 1, 2029. After this transition period, declarations of conformity to Rec# 5-135 will not be accepted."

This establishes a clear, multi-year transition architecture:

Immediate Action: New premarket submissions (510(k), De Novo, PMA) may immediately cite Rec# 5-149 (ISO 20417:2026).
Grace Period Acceptance: Submissions currently in preparation or utilizing established testing and labeling referencing Rec# 5-135 remain fully valid and acceptable to FDA reviewers until July 1, 2029.
Marketed Products: Existing commercially distributed medical devices whose technical files cite the 2021 edition do not require an emergency labeling revision or submission. Updates can be integrated during routine design changes or subsequent submissions.

To verify how the transition period operates in FDA's Standards and Conformity Assessment Program (S-CAP), see our foundational guide on Transition Periods and Superseded Standards.

Empirical Corroboration: FDA Consensus Standards Database Analysis

An analysis of the normalized dataset of FDA Recognized Consensus Standards (snapshot dated August 26, 2026) confirms the administrative status across CDRH's database:

Recognition Number	Designation & Edition	Date of Entry	Extent of Recognition	Transition Expiration Date
Rec# 5-149	ISO 20417 Second edition 2026-03	05/25/2026	Complete	(Active Complete Recognition)
Rec# 5-135	ISO 20417 First edition 2021-04 (Corr. 2021-12)	12/19/2022	Complete	07/01/2029

Data context: A 26 August 2026 snapshot of the normalized FDA recognized-consensus-standards database contained 1,898 rows and 1,740 unique recognition numbers. Seventy-four rows (65 unique recognition numbers) share the 25 May 2026 date of entry associated with Recognition List 066. Rec# 5-149 is the only General I (Quality System / Risk Management) recognition number in that 25 May 2026 entry batch; it is not the only General I standard in the live database (ISO 15223-1 Rec# 5-148, for example, remains current). Sibling standards on List 066 include ISO 10993-1 Sixth edition (Rec# 2-313) under Biocompatibility. These figures are database snapshot counts, not a census of labeled devices or of Declarations of Conformity filed.

Voluntary Nature of Consensus Standards under FD&C Act Section 514(c)

Declaration of Conformity to an FDA-recognized consensus standard is an elective, streamlined mechanism to demonstrate substantial equivalence in a 510(k) or safety and effectiveness in a De Novo or PMA. As established in the FDA guidance Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices:

Standards are Voluntary: A manufacturer is never legally compelled to use an FDA-recognized standard. If a manufacturer chooses not to declare conformity to ISO 20417:2026, it may demonstrate compliance with 21 CFR Part 801 through alternative, justified engineering and clinical methodologies.
Extent of Recognition: Complete recognition of ISO 20417:2026 means FDA has accepted all clauses without technical exceptions. However, this does not mean every clause is applicable to every device type (e.g., single-use implantable devices vs complex active capital equipment).

How Does ISO 20417 Differ from ISO 15223-1, eIFU Rules, and 21 CFR 801.15 Symbols?

Regulatory and labeling professionals must maintain clear structural boundaries between content standards, symbol standards, delivery regulations, and statutory labeling laws.

Regulatory Dimension	ISO 20417:2026	ISO 15223-1:2021 + AMD1:2025	21 CFR Part 801 / 801.15	EU MDR GSPR 23 / IVDR GSPR 20	eIFU Rules
Primary Domain	What information to supply	How to visually represent information	Mandatory U.S. statutory labeling laws	Mandatory EU statutory information rules	Formats & rules for digital delivery
Standard / Rule Type	Voluntary horizontal standard	Voluntary graphical symbol standard	Federal statutory regulation	European Union statutory regulation	Implementing regulations & guidance
FDA Recognition	Rec# 5-149 (DoC to 5-135 accepted to July 1, 2029)	Rec# 5-148 (DoC to 5-134 accepted to Dec 17, 2028)	Codified in Code of Federal Regulations	Codified in MDR 2017/745 and IVDR 2017/746	FD&C Act § 502(f); 21 CFR Part 801
Key Output Requirement	Content of labels, IFUs, packaging, accompanying files	Standardized symbol geometries and titles	English prominence, UDI, symbols glossary, warnings	Multi-language translation, GSPR matrix, UDI	Secure web hosting, uptime, 7-day paper delivery

ISO 20417 (Content) vs. ISO 15223-1 (Symbols)

The fundamental difference between ISO 20417 and ISO 15223-1 is the difference between information requirements and symbolic expression:

ISO 20417 specifies what data points must accompany the device (e.g., batch/lot number, manufacturer name and address, expiry date, sterile barrier status, storage conditions, operational warnings).
ISO 15223-1 defines the graphical symbols that may be utilized to convey those specific data points without relying on translated text.

For comprehensive analysis of symbol governance, including Amendment 1:2025 and the European Authorized Representative symbol rules, refer to our dedicated guide on What is the difference between ISO 15223-1 and ISO 20417?.

The U.S. Stand-Alone Symbol Rule: 21 CFR 801.15

Under the FDA Final Rule Use of Symbols in Labeling (81 FR 38911, codified at 21 CFR 801.15), a manufacturer may use a stand-alone graphical symbol (a symbol without adjacent explanatory English text) on a medical device label only if the label or labeling also includes a symbols glossary, and one of the following is true:

The symbol is in a standard recognized by FDA under Section 514(c) of the FD&C Act (such as ISO 15223-1, recognized under Rec# 5-148), and it is used according to the specifications in FDA's recognition; or
The symbol is established in a standards-development-organization (SDO) standard that FDA has not recognized, or is in a recognized standard but is not used according to FDA's recognition, and the manufacturer determines that the symbol is likely to be read and understood by the ordinary individual under customary conditions of purchase and use.

The prescription-only Rx only statement is authorized separately under Section 503(b)(4) of the FD&C Act and 21 CFR 801.109; it is not a third 801.15(c) pathway created by ISO 20417.

ISO 20417 does not grant stand-alone symbol authority. Citing ISO 20417 in a submission does not exempt a manufacturer from 21 CFR 801.15 symbols glossary requirements. For further details on U.S. labeling statutory mandates, see FDA Labeling Requirements (21 CFR Part 801).

Delivery Media: Why eIFU Rules Control Format

When marketing in the EU or US, the legality of replacing printed paper IFUs with electronic formats is governed by dedicated delivery rules, not by ISO 20417:

European Union: Governed by Commission Implementing Regulation (EU) 2021/2226 as amended by Regulation (EU) 2025/1234. As of the 2025 amendment, eIFU is permitted for software (including software used by lay persons, when provided through the software itself) and for medical devices intended for professional use. Paper IFU must still be supplied free of charge within 7 calendar days upon request. Do not treat the pre-2025 implant-and-fixed-installation list as the current eligibility rule; see Why eIFU Matters for Medical Device Manufacturers.
United States: FD&C Act section 502(f) (21 U.S.C. 352(f)) permits required labeling for prescription devices intended for use in health care facilities or by a health care professional, and required labeling for IVDs intended for use by health care professionals or in blood establishments, to be made available solely by electronic means, provided the labeling complies with applicable law and the manufacturer promptly supplies a paper copy without additional cost upon request. Overlay remains 21 CFR Part 801.

ISO 20417:2026 respects these jurisdictional boundaries by remaining silent on format mandates. To evaluate electronic delivery eligibility, consult the eIFU guide linked above.

Does CEN Publication of EN ISO 20417:2026 Give EU MDR Presumption of Conformity?

In the European Union, the relationship between European standards adopted by the European Committee for Standardization (CEN) and regulatory compliance under EU MDR 2017/745 is frequently misunderstood.

Legal Requirement: Annex I, Chapter III (GSPR 23)

The statutory obligation for medical devices placed on the EU market is compliance with General Safety and Performance Requirement 23 (GSPR 23) in Annex I of the MDR. For IVDs, the parallel information requirement is GSPR 20 in Annex I of the IVDR — not GSPR 23. MDR GSPR 23 is divided into detailed sub-clauses:

GSPR 23.1: General requirements regarding the information supplied by the manufacturer;
GSPR 23.2: Information on the label;
GSPR 23.3: Information on the packaging which maintains the sterile condition of a device;
GSPR 23.4: Information in the instructions for use.

To review the complete regulatory checklist and evidence mapping for GSPR 23, consult Chapter III: Requirements Regarding the Information Supplied with the Device (GSPR 23).

The Mechanism of Presumption of Conformity (MDR Article 8)

Under Article 8(1) of EU MDR 2017/745, a device is presumed to be in conformity with the requirements of the Regulation (including GSPR 23) only to the extent that it complies with relevant harmonised standards (or parts thereof) the references of which have been published in the Official Journal of the European Union (OJEU).

The crucial distinction for European regulatory strategy:

CEN Publication is NOT Harmonisation: When CEN adopts an ISO standard as a European Standard (EN ISO 20417:2026), it becomes a national standard across all EU Member States. However, CEN publication alone does not confer legal presumption of conformity.
Commission Standardization Request M/575: The European Commission issued Standardization Request M/575 to CEN/CENELEC for standards supporting MDR and IVDR. While ISO 20417 is included in the M/575 work program with a delivery timeline running through May 27, 2028, that date represents a standardization request deadline, not an active OJEU citation.
Current OJEU Status: As of 31 August 2026, EN ISO 20417:2026 has not been cited as a harmonised standard in Commission Implementing Decision (EU) 2021/1182 as last amended by Commission Implementing Decision (EU) 2026/1231 (OJ L 17.6.2026). That June 2026 decision updates symbols and information-supplied references by citing EN ISO 15223-1:2021/A1:2025, not EN ISO 20417:2026. Check the Commission harmonised-standards page before treating any CEN publication as Article 8 presumption of conformity.

How Notified Bodies Evaluate ISO 20417: State of the Art (SOTA)

Even without an OJEU harmonisation citation, European Notified Bodies (such as TÜV SÜD, BSI, DEKRA, and TÜV Rheinland) evaluate technical documentation against the State of the Art (SOTA) under MDR Annex II.

Because ISO 20417:2026 represents the current international consensus on information supplied by manufacturers, Notified Bodies expect manufacturers to:

Conduct a documented gap analysis comparing their current labeling and IFU architecture against ISO 20417:2026;
Demonstrate that any deviations do not compromise clinical safety, user comprehension, or GSPR 23 (MDR) / GSPR 20 (IVDR) compliance;
Record the SOTA justification in the GSPR evidence matrix and technical documentation (Annex II), with any related residual-risk discussion in the risk-management file. Labeling SOTA is not, by itself, a Clinical Evaluation Plan (CEP) deliverable.

For an in-depth analysis of managing the gap between published standards and OJEU citations, see our analysis on The "State of the Art" Problem.

What Fails If You Treat the 2021 Edition as Immediately Illegal, or Copy Consultant Readability Scores as ISO Text?

Navigating a major standard update requires avoiding common regulatory failure modes generated by alarmist marketing or superficial compliance audits.

Failure Mode	Root Cause / False Assumption	Operational & Regulatory Impact	Correct Regulatory Execution
1. Emergency Relabeling Crisis	Assuming ISO catalogue cancellation immediately invalidates technical files at FDA	Wastes substantial engineering capital and disrupts packaging supply chains	Leverage the FDA July 1, 2029 DoC transition window; update files during scheduled design changes
2. Blindly Adopting Readability Indexes	Assuming ISO 20417 mandates rigid Flesch-Kincaid / SMOG scoring formulas	Commits QMS SOPs to unfulfillable audits across non-English language packaging	Establish comprehensibility via IEC 62366-1 usability testing and risk analysis
3. Conflating ISO 15223-1 Symbols with 20417	Attempting to solve EU-REP symbol revisions in an ISO 20417 gap assessment	Creates scope errors in design inputs and overlooks ISO 15223-1 Amd 1:2025	Use ISO 15223-1 for symbol artwork and ISO 20417 for core information structure
4. Claiming ISO 20417 Supersedes Law	Asserting that ISO 20417 replaces 21 CFR 801 or MDR GSPR 23	Triggers immediate regulatory deficiency letters and rejection by reviewers	Present ISO 20417 as voluntary consensus evidence supporting underlying statutes
5. Treating CEN Adoption as OJEU Harmonisation	Assuming European Standard publication grants MDR Article 8 presumption	Fails technical file audits during Notified Body review	Document compliance as State of the Art (SOTA) in the GSPR matrix until OJEU citation

Failure Mode 1: Initiating an Unnecessary Relabeling Emergency

Several regulatory consultant blogs published alerts asserting that because ISO canceled the 2021 edition upon publication of the 2026 edition, any medical device currently shipping with technical files referencing ISO 20417:2021 is non-compliant.

The Reality: Standards development organizations cancel superseded editions as a matter of internal catalogue management. National regulatory authorities determine transition timelines. In the United States, FDA published Rec# 5-149 with an explicit transition allowing Declarations of Conformity to Rec# 5-135 through July 1, 2029. Existing marketed devices in commercial distribution require no emergency label change or recall.

Failure Mode 2: Copying Consultant Readability Scores as Mandatory ISO Clauses

Certain commercial blog articles claim that ISO 20417:2026 mandates specific quantitative readability indexes (e.g., Flesch-Kincaid Grade Level 7–8, SMOG scoring, or specific font-point formulas) for all patient-facing labeling.

The Reality: While ISO 20417 emphasizes legibility, comprehensibility, and user-appropriate language, it does not impose a single rigid readability index. Mandating specific mathematical formulas across multi-language international packaging (where English readability formulas are linguistically meaningless) creates severe compliance vulnerabilities during Notified Body and FDA QMSR audits. Readability must be established through validated usability engineering and human factors testing under IEC 62366-1.

Failure Mode 3: Conflating ISO 15223-1 EU-REP Symbols with ISO 20417

Following the publication of ISO 15223-1:2021 / Amd 1:2025 regarding the representation of the European Authorized Representative and importer information, several teams attempted to address symbol changes through ISO 20417 gap assessments.

The Reality: Graphical symbol geometry, standardization, and stand-alone symbol rules belong exclusively to ISO 15223-1 and 21 CFR 801.15. ISO 20417 defines the requirement to identify the manufacturer and authorized representative, but points to ISO 15223-1 for the corresponding symbol.

Failure Mode 4: Telling Regulatory Reviewers ISO 20417 Superseded 21 CFR 801 or GSPR 23

Submitting a 510(k) or EU MDR technical file asserting that labeling is compliant "because it strictly follows ISO 20417:2026, which supersedes local labeling rules" will result in immediate regulatory deficiency letters.

The Reality: The FDA Supplementary Information Sheet and ISO 20417 Scope explicitly note that specific legal requirements of the Authority Having Jurisdiction (AHJ) take precedence. 21 CFR Part 801 in the US and GSPR 23 in the EU are statutory mandates that cannot be displaced by voluntary consensus standards.

ISO 20417 30/60/90-Day DoC, Label-Content, and Technical-File Plan

Manufacturers should execute a disciplined, phased transition to ISO 20417:2026 across their global product portfolios.

Timeframe	Key Focus Area	Deliverables & Work Streams	Primary Regulatory Objective
Days 1–30	Portfolio Audit & Gap Assessment	• Procure ISO 20417:2026 • Inventory active DoCs & 510(k) pipeline • Map "applicable policy" to 21 CFR 801, MDR GSPR 23, and IVDR GSPR 20 • Identify overriding vertical standards (e.g. ISO 80369)	Establish formal gap baseline without triggering panic redesigns
Days 31–60	Technical Documentation Updates	• Update 510(k) DoC templates to cite Rec# 5-149 • Revise EU MDR GSPR 23 SOTA evidence matrices • Reconcile ISO 15223-1+A1:2025 symbols & glossaries • Audit digital labeling against eIFU regulations	Ensure all upcoming regulatory filings reflect current recognized standards
Days 61–90	QMS & Supply Chain Implementation	• Release Design Change Orders (ECOs) for packaging • Update translation vendor SLAs & glossaries • Align PMS / vigilance for usability complaints • Conduct cross-functional labeling training	Operationalize revised label content into routine quality system workflows

Days 1–30: Portfolio Audit and Gap Assessment

Procure the Official Standard: Purchase an authorized copy of ISO 20417:2026 (Second edition 2026-03) from ISO, ANSI, AAMI, or national standards bodies.
Inventory Premarket DoCs: Audit all active U.S. premarket submissions in development. Determine which submissions will cite Rec# 5-149 (ISO 20417:2026) immediately versus those maintaining Rec# 5-135 within the transition window ending July 1, 2029.
Perform Horizontal Gap Analysis: Compare existing labeling SOPs and packaging templates against ISO 20417:2026 revisions, focusing on updated normative references and the "applicable policy" concept.
Audit Vertical Standards Precedence: Identify all device-specific standards applicable to your portfolio (e.g., ISO 80369 for small-bore connectors, IEC 60601-1-11 for home healthcare equipment) to confirm where vertical labeling clauses override ISO 20417.

Days 31–60: Technical Documentation and Submission Alignment

Update U.S. 510(k) / De Novo Templates: Transition Declaration of Conformity templates for upcoming premarket filings to cite FDA Rec# 5-149 (Recognition List 066).
Update EU MDR GSPR 23 / IVDR GSPR 20 Evidence Matrix: In the Technical Documentation (Annex II/III), update the information-supplied checklist to reference EN ISO 20417:2026 as current State of the Art (SOTA), while referencing MDR GSPR 23 or IVDR GSPR 20 as the governing legal requirement.
Reconcile ISO 15223-1 Symbols: Ensure all symbol artwork on primary labels, secondary cartons, and IFUs conforms to ISO 15223-1:2021+A1:2025 and 21 CFR 801.15 Symbols Glossary requirements.
Review eIFU Risk Assessments: If providing digital labeling, verify compliance with Commission Regulation (EU) 2021/2226 / 2025/1234 or FDA eIFU policies.

Days 61–90: QMS Integration and Supply Chain Execution

Execute Labeling Engineering Change Orders (ECOs): Implement required text and artwork adjustments through formal design-and-development change control under the Quality Management System Regulation (21 CFR Part 820, which incorporates ISO 13485:2016) and ISO 13485:2016.
Align Translation Service Level Agreements (SLAs): Ensure translation vendors utilize updated ISO 20417 and ISO 15223-1 terminology glossaries across all official target market languages.
Establish Post-Market Labeling Surveillance: Incorporate user feedback, usability complaints, and MAUDE / vigilance reports regarding label comprehensibility into the Periodic Safety Update Report (PSUR) and Post-Market Surveillance (PMS) plan.
Conduct Internal Regulatory Training: Train labeling design, regulatory affairs, and packaging engineering personnel on the distinction between ISO 20417 content, ISO 15223-1 symbols, and statutory labeling mandates.

What Does This Cost: ISO Purchase and Artwork versus FDA MDUFA and the Absence of a 20417 User Fee?

Budgeting for ISO 20417:2026 compliance requires a strict distinction between statutory government fees and commercial engineering expenses.

Expense Category	Responsible Entity / Vendor	Typical Cost Range	Regulatory & Operational Basis
Statutory Standards Fee	U.S. FDA / EU Authorities	$0.00	There is no government fee or tariff to adopt a recognized consensus standard.
FDA Premarket User Fee	U.S. FDA (MDUFA FY 2027)	$7,163 – $28,653 (Conditional 510(k))	Official FY 2027 MDUFA 510(k) small-business / standard rates. Apply only if a labeling change triggers a feeable premarket submission.
Official Standard Copy	ISO / ANSI / AAMI / BSI	Typical ~$200 – $350 per license	Provider list price; MedDeviceGuide typical commercial estimate, not an official tariff.
Label & Carton Redesign	Design Agency / Internal	Typical $1,500 – $10,000+ per line	MedDeviceGuide typical commercial estimate for artwork, proofs, and plates.
Certified Translations	Medical Translation Provider	Typical $0.15 – $0.30 per word/lang	MedDeviceGuide typical commercial estimate; not an authority fee schedule.
Usability Comprehension	Human Factors Lab / CRO	Typical $15,000 – $50,000+ (Complex)	MedDeviceGuide typical commercial estimate for IEC 62366-1 protocols.

Statutory Government Fees: No ISO 20417 Tariff

There is no government fee charged by FDA, the European Commission, or national competent authorities to "use," adopt, or cite ISO 20417:2026.

U.S. Medical Device User Fee Amendments (MDUFA) fees attach strictly to premarket submissions. For Fiscal Year 2027 (1 October 2026 through 30 September 2027), the official standard 510(k) user fee is $28,653 ($7,163 for qualified small businesses). See the on-site FY 2027 MDUFA rate table. If a manufacturer modifies labeling in a manner that does not affect intended use or fundamental scientific technology (governed under FDA guidance Deciding When to Submit a 510(k) for a Change to an Existing Device), the change is documented in an internal letter-to-file without paying any FDA submission fee.

Commercial and Engineering Expenses

Standard Procurement: Direct licensing fees to ISO, ANSI, or AAMI for single or multi-user copies of ISO 20417:2026 (typically about $200–$350 per copy; provider list prices, not government fees).
Packaging and Artwork Tooling: Modifying carton artwork, IFU booklets, and printing plates across multiple stock keeping units (SKUs) is usually the largest physical expense (typically $1,500 to $10,000+ per product line; MedDeviceGuide commercial estimate).
Medical Translation Costs: Under EU MDR Article 10(11), manufacturers must provide labeling and IFUs in the official languages determined by each EU Member State (up to 24 languages). Certified medical translations commonly fall around $0.15 to $0.30 per word per language (commercial estimate, not an authority tariff).
Usability Validation: For high-risk, complex, or home-use devices, verifying that label information and warnings are effectively understood may require human factors comprehension testing under IEC 62366-1 (typically $15,000 to $50,000+ depending on protocol complexity; commercial estimate).

Frequently Asked Questions (FAQs)

Did FDA make ISO 20417:2026 mandatory for every 510(k) on August 24, 2026?

No. Declarations of conformity to FDA-recognized consensus standards under Section 514(c) of the FD&C Act are entirely voluntary. Furthermore, in Recognition List 066, FDA established a formal transition period allowing manufacturers to submit Declarations of Conformity to Rec# 5-135 (ISO 20417:2021) in premarket submissions through July 1, 2029.

Until when will FDA accept a Declaration of Conformity to ISO 20417:2021 Rec# 5-135?

FDA will accept Declarations of Conformity citing Rec# 5-135 (ISO 20417 First edition 2021-04 Corrected version 2021-12) until July 1, 2029. After July 1, 2029, premarket submissions electing to declare conformity to ISO 20417 must cite Rec# 5-149 (Second edition 2026-03).

Does ISO 20417 tell us whether to use paper IFU, eIFU, or a QR code?

No. ISO 20417 defines what information needs to be supplied with a medical device, but explicitly does not specify the delivery means or format. The legality of using electronic instructions for use (eIFU) is governed by specific rules, including Regulation (EU) 2021/2226 as amended by Regulation (EU) 2025/1234 in the European Union, and FD&C Act section 502(f) (21 U.S.C. 352(f)) plus 21 CFR Part 801 in the United States.

Is ISO 20417 the same as ISO 15223-1?

No. ISO 20417 is the horizontal content standard defining the specific information elements required to accompany a device. ISO 15223-1 is the graphical symbol standard defining the standardized symbols used on labels and packaging to convey that information without language barriers (recognized by FDA under Rec# 5-148).

Is EN ISO 20417:2026 a harmonised standard under MDR/IVDR?

Not automatically. Adoption by CEN as a European standard (EN ISO 20417:2026) is a technical standardization step. Under Article 8 of EU MDR 2017/745, legal presumption of conformity requires formal citation in the Official Journal of the European Union (OJEU). Commission Implementing Decision (EU) 2026/1231 updated the MDR harmonised list in June 2026 (including EN ISO 15223-1:2021/A1:2025) but did not cite EN ISO 20417:2026. Manufacturers must treat ISO 20417:2026 as State of the Art (SOTA) in their MDR GSPR 23 / IVDR GSPR 20 matrices until an OJEU citation exists.

Is there an FDA or CMS fee to switch labeling to ISO 20417:2026?

No. There is no statutory government user fee to adopt or declare conformity to ISO 20417. U.S. MDUFA fees apply only if a labeling change triggers a new premarket submission (such as a 510(k), De Novo, or PMA supplement). Standard procurement, artwork redesign, translations, and gap assessments are commercial and internal engineering costs.

How Pure Global Supports Global Medical Device Labeling and Regulatory Compliance

Navigating international labeling standards, FDA consensus recognition windows, and European GSPR 23 mandates requires rigorous technical coordination across regulatory affairs, quality assurance, and packaging engineering. Pure Global provides comprehensive regulatory strategy, technical documentation authoring, and international market clearance services for medical device and IVD manufacturers worldwide.

Key support capabilities include:

U.S. FDA Premarket Submissions & Standards Strategy: Structuring Declarations of Conformity across FDA Recognized Consensus Standards, navigating Recognition List 066 transition windows, and compiling 510(k), De Novo, and PMA filings through our United States Market Access Practice.
EU MDR & IVDR Technical Documentation: Drafting Annex II/III technical files, aligning GSPR 23 evidence matrices, and defending State of the Art (SOTA) compliance during Notified Body audits via our EU MDR Consulting Services.
Labeling & eIFU Compliance Audits: Conducting comprehensive gap assessments against ISO 20417:2026, ISO 15223-1:2021+A1:2025, 21 CFR Part 801, and Regulation (EU) 2021/2226 / 2025/1234.
Global In-Country Representation: Providing Authorized Representative services and managing global regulatory communications across major international markets.

To audit your device labeling strategy or structure your next premarket submission, contact Pure Global.

Pure Global provides independent regulatory affairs, quality systems, and market-access advisory services. Pure Global is not the U.S. Food and Drug Administration (FDA), the International Organization for Standardization (ISO), a European Notified Body, or an EU Competent Authority, and does not issue statutory government licenses or conformity certificates.

Sources

ISO 20417:2026 Medical devices — Information to be supplied by the manufacturer — International Organization for Standardization (Second edition, March 2026).
FDA Recognized Consensus Standards: ISO 20417 Second edition 2026-03, Rec# 5-149 — U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH).
Modifications to the List of Recognized Standards, Recognition List Number: 066 — U.S. Food and Drug Administration / Federal Register (91 FR 54715–54721, FR Doc. 2026-17229, Applicable August 24, 2026).
21 CFR Part 801 — Medical Devices; Labeling — Electronic Code of Federal Regulations, U.S. Government Publishing Office.
21 CFR 801.15 — Medical devices; prominence of required label statements; use of symbols in labeling — eCFR / U.S. Government Publishing Office.
Principles of Labelling for Medical Devices and IVD Medical Devices (IMDRF/GRRP WG/N52 FINAL:2024) — International Medical Device Regulators Forum (Edition 2, April 26, 2024).
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices — U.S. Food and Drug Administration (September 2018).
Regulation (EU) 2017/745 on medical devices (EU MDR) — European Parliament and Council of the European Union (Annex I, Chapter III, GSPR 23).
Regulation (EU) 2017/746 on in vitro diagnostic medical devices (EU IVDR) — European Parliament and Council of the European Union (Annex I, Chapter III, GSPR 20).
Harmonised Standards for Medical Devices under MDR/IVDR — European Commission, Directorate-General for Health and Food Safety.
Commission Implementing Regulation (EU) 2021/2226 on electronic instructions for use — European Commission (as amended by Regulation (EU) 2025/1234).
FDA Recognized Consensus Standards: ISO 15223-1 Fourth edition 2021-07 including AMD1:2025, Rec# 5-148 — U.S. Food and Drug Administration (DoC to Rec# 5-134 accepted until December 17, 2028).
Medical Device User Fee Amendments (MDUFA) Fees — U.S. Food and Drug Administration (FY 2027 schedule: 510(k) $28,653 standard / $7,163 small business).
21 U.S.C. § 352(f) — Misbranded drugs and devices (electronic labeling for specified professional-use devices) — United States Code.
Commission Implementing Decision (EU) 2026/1231 — European Commission (amends Decision (EU) 2021/1182; cites EN ISO 15223-1:2021/A1:2025, not EN ISO 20417:2026).